Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&U Detrol Campaign Finds Detractors in U.K Consumer Group

Executive Summary

The U.K.' s Consumer Association has asked the Blair government to review its policies on Rx advertising in the wake of the disease awareness TV campaign for Pharmacia & Upjohn's overactive bladder therapy Detrol/Detrusitol (tolterodine), launched Sept. 1.

You may also be interested in...



Glaxo Decides Not To Pursue U.K. Flu Awareness Campaign For Relenza

The potential negative impact on the U.K.' s National Health Service drug budget may be one factor behind Glaxo Wellcome's decision not to launch a flu awareness campaign for its neuraminidase inhibitor Relenza (zanamivir) in the U.K.

Print Component Of Broadcast DTC Ads Should Have Equal Reach

The print component of direct-to-consumer advertising campaigns for prescription drugs should seek to reach the "target audience" to the same degree as broadcast ads, FDA's final guidance on "Consumer-Directed Broadcast Advertisements" says.

Medicare Could Pay $92 Bil. For Drugs in 2008 At Highest Subsidy Level

The Clinton Administration's Medicare drug benefit could cost the government as much as $92 bil. in drug expenditures for the elderly in the year 2008 when the benefit is fully in place.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel